HIGH COMPLETE REMISSION RATE FROM 2-CHLORO-2'-DEOXYADENOSINE IN PREVIOUSLY TREATED PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA - RESPONSE PREDICTED BY RAPID DECREASE OF BLOOD LYMPHOCYTE COUNT

被引:146
作者
JULIUSSON, G [1 ]
LILIEMARK, J [1 ]
机构
[1] KAROLINSKA INST,KAROLINSKA HOSP,DEPT CLIN PHARMACOL,S-10401 STOCKHOLM 60,SWEDEN
关键词
D O I
10.1200/JCO.1993.11.4.679
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study attempted to characterize the response of previously treated patients with B-cell chronic lymphocytic leukemia (CLL) to the purine analog 2-chloro-2′-deoxyadenosine (CdA) and to assess factors that predict response. Patients and Methods: We treated 18 CLL patients with about-monthly courses of five daily 2-hour intravenous infusions of 0.12 mg Cd A/kg. Results: Complete remissions (CRs) were achieved in seven patients (39%), with a total response rate of 67%. CR patients received a median of 4.5 courses. One patient with CR relapsed and died 14 months from start of CdA treatment, whereas the other six patients with CR remain in remission following a mean observation period of 14 months. The median duration of partial remissions (PRs) was 9 months, with a median treatment-free interval of 15 months. Thrombocytopenia was the most common dose-limiting toxicity. Non-responding patients had a median survival of 3.5 months, and systemic fungal infections were the most common cause of death. Immunoglobulin (Ig) levels improved significantly in hypogammaglobulinemic patients during CdA treatment. Responses were predicted by a rapid decrease of blood lymphocyte counts following the first treatment course. Conclusion: A high CR rate was achieved with limited toxicity. A treatment strategy to enable high-quality response and limitation of treatment-related toxicity is provided. © 1993 by American Society of Clinical Oncology.
引用
收藏
页码:679 / 689
页数:11
相关论文
共 30 条
[1]   CLADRIBINE (2-CHLORODEOXYADENOSINE) [J].
BEUTLER, E .
LANCET, 1992, 340 (8825) :952-956
[2]  
BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO
[3]  
2-V
[4]   ANTILEUKEMIC AND IMMUNOSUPPRESSIVE ACTIVITY OF 2-CHLORO-2'-DEOXYADENOSINE [J].
CARSON, DA ;
WASSON, DB ;
BEUTLER, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (07) :2232-2236
[5]   GUIDELINES FOR CLINICAL PROTOCOLS FOR CHRONIC LYMPHOCYTIC-LEUKEMIA - RECOMMENDATIONS OF THE NATIONAL-CANCER-INSTITUTE-SPONSORED-WORKING-GROUP [J].
CHESON, BD ;
BENNETT, JM ;
RAI, KR ;
GREVER, MR ;
KAY, NE ;
SCHIFFER, CA ;
OKEN, MM ;
KEATING, MJ ;
BOLDT, DH ;
KEMPIN, SJ ;
FOON, KA .
AMERICAN JOURNAL OF HEMATOLOGY, 1988, 29 (03) :152-163
[6]  
CHUNDURU S K, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P17
[7]  
JULIUSSON G, 1992, BLOOD, V79, P888
[8]  
JULIUSSON G, 1985, BLOOD, V65, P134
[9]   RESPONSE TO 2-CHLORODEOXYADENOSINE IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA RESISTANT TO FLUDARABINE [J].
JULIUSSON, G ;
ELMHORNROSENBORG, A ;
LILIEMARK, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (15) :1056-1061
[10]  
JULIUSSON G, 1992, BLOOD S, V80, P3592